Pfizer, Bristol-Myers tout new VTE data on Eliquis, aiming for new use

Tracy Staton When is non-inferiority actually superior? When you're talking about new substitutes for the difficult-to-administer warfarin. So, Pfizer and Bristol-Myers Squibb happily ...

Bonviva IV Injection OKd in Japan

barbara.lempert New Agent for Osteoporosis Approved in Japan “Bonviva® IV Injection” June 28, 2013 (Tokyo) – Chugai Pharmaceutical Co., Ltd. (Chugai) [Head Office: Chuo-ku, ...

FDA scraps Merck’s high-dose sleep drug, demands weaker version

John Carroll Fretting over the potential for serious side effects, the FDA has batted aside Merck's ($ MRK) application to sell the new insomnia drug suvorexant, ...

FDA OKs Latuda for Bipolar Depression

barbara.lempert Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression First ...

Report: China rounds up GlaxoSmithKline staffers in corruption probe

John Carroll FierceBiotech News

Bayer, Onyx Submit Nexavar for Thyroid Cancer to FDA, EMA

barbara.lempert Bayer and Onyx Pharmaceuticals Announce Submission of FDA and EMA Applications for Nexavar® (sorafenib) for the Treatment of Radioactive Iodine-Refractory ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS